$CRVS Cashflow Statement | Understand Stock

$CRVS

$10.45 -$0.08 (0.76%) Close

$CRVS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Accretion related to marketable securities
Stock-based compensation
Gain from sale of property and equipment
Change in fair value of warrant liability
Loss from equity method investment
Changes in operating assets and liabilities:
Accounts receivable
Prepaid and other current assets
Operating lease right-of-use asset
Other assets
Accounts payable
Accrued and other liabilities
Operating lease liability
Net cash used in operating activities
Cash flows from investing activities
Purchases of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Proceeds from sale of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Proceeds from issuance of common stock, net (includes $1,794 in aggregate gross proceeds from related parties)
Related party
Total proceeds from issuance of common stock, net (includes $1,794 in aggregate gross proceeds from related parties)
Proceeds from issuance of pre-funded warrants, net (includes $1,769 in aggregate gross proceeds from related parties)
Related party
Total proceeds from issuance of pre-funded warrants, net (includes $1,769 in aggregate gross proceeds from related parties)
Proceeds from issuance of common warrants (includes $1,472 in aggregate gross proceeds from related parties)
Related party
Total proceeds from issuance of common warrants (includes $1,472 in aggregate gross proceeds from related parties)
Proceeds from the exercise of common stock warrants (includes $4,960 in aggregate gross proceeds from related parties for the year ended December 31, 2025)
Related party
Total proceeds from the exercise of common stock warrants (includes $4,960 in aggregate gross proceeds from related parties for the year ended December 31, 2025)
Proceeds from issuance of common stock in connection with at-the-market offering, net
Proceeds from exercise of common stock options
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of the period
Cash and cash equivalents at end of the period
Supplemental disclosures of cash flow information
Purchases of property and equipment incurred but not paid
Reclassification of common stock warrant liability into additional paid-in capital upon exercise of common stock warrants
Right-of-use asset obtained in exchange for operating lease liability

Comments